Evaluation of different doses of surfactant curosurf’s efficacy in treating premature infants with respiratory distress syndrome

Respiratory distress syndrome is the main cause of respiratory failure in premature neonates that results in high morbidity and mortality during the perinatal period. Surfactant is the main drug used to treat RDS but the primary dosing of it is still up for debate. The aim of this study was to compare the efficacy of two doses of surfactant “Curosurf” in treating neonatal RDS. As a prospective, randomised investigation could not be completed, a retrospective review involving 73 premature infants with RDS treated with surfactant in NICU of LUHS Hospital Kaunas Clinics in 2011-2012 was conducted. Newborns were treated for respiratory distress syndrome with 88-150 mg/kg (group A) and 151-200 mg/kg (group B) of Curosurf. The duration of supplemental oxygen therapy and its methods, need for additional surfactant doses, bronchopulmonary dysplasia and its severity, hospitalisation and mortality rates were compared. Statistical analysis was performed using Student's criterion for quantitative and Chi square for qualitative characteristics. The results were considered statistically significant at p